A Phase 1/2 interventional study of Chaixia Dingzhi Powder and Placebo Group in Obsessive-Compulsive Disorder, OCD and Traditional Chinese Medicine (TCM), sponsored by Shanghai Mental Health Center. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shanghai Mental Health Center · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.
Among the 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 9 of the 14 other live ones, and was the 27th registered.
636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 165 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →15 of the 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–50
Shanghai Mental Health Center · Sites in China
Ages 18–65
Shanghai Mental Health Center · Sites in China
Ages 7–17 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–60
Shanghai Mental Health Center · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 45 across 520 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 60 across the 24 interventional studies, 125 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 274 studies on the registry; 93 are open to participants now.
7 of the studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07115615Shanghai Mental Health CenterExploring the Efficacy of Accelerated Transcranial Direct Current Stimulation (tDCS) as Adjunct to Pharmacotherapy in the Treatment of Obsessive-compulsive Disorder | 2026-12-31 |
| NCT07031544Shanghai Mental Health CenterEfficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder | 2027-03-31 |
| NCT07113652Shanghai Mental Health CenterThe Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder | 2027-06 |
| NCT04539951Shanghai Mental Health CenterPragmatic Trial of Obsessive-compulsive Disorder | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 27 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent intrusive obsessive thoughts, urges, and ritualized compulsive behaviors. OCD often follows a chronic and protracted course with a high risk of relapse and is frequently accompanied by comorbid anxiety, depression, and other negative emotional symptoms, resulting in substantial impairment in occupational functioning, interpersonal relationships, and family and social functioning.Integrative treatment combining traditional Chinese medicine (TCM) and Western medicine may help address several limitations of conventional monotherapy, including suboptimal treatment response rates, medication-related adverse effects, the limited diversity of available therapeutic approaches, and insufficiently individualized treatment strategies, thereby offering potential clinical benefits.Chaixia Dingzhi Powder, the investigational Chinese herbal formula used in this study, was developed based on the formulation principles of two classical TCM prescriptions, Xiaoyao San (Free and Easy Wanderer Powder), documented in the Taiping Huimin Heji Jufang (Formulary of the Pharmacy Service for Benefiting the People in the Taiping Era), and Banxia Houpo Tang (Pinellia and Magnolia Bark Decoction), recorded in the Jingui Yaolue (Essentials from the Golden Cabinet). The formula was further modified according to the TCM pathophysiological characteristics of the target population, particularly liver qi stagnation with spleen deficiency, impaired qi movement, and the interaction of phlegm and qi stagnation.Therefore, this study aims to further investigate the efficacy and safety of Chaixia Dingzhi Powder as an adjunctive traditional Chinese medicine (TCM) treatment in patients with obsessive-compulsive disorder (OCD) who have demonstrated nonresponse to initial SSRI treatment, while maintaining their existing SSRI therapy at an adequate therapeutic dose or the maximum tolerated dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1)Aged 16-65 years; 2)Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the , Fifth Edition (DSM-5); 3)Have received continuous SSRI monotherapy at the maximum recommended dose or maximum tolerated dose for at least 8 consecutive weeks; 4)Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score >12 or a Clinical Global Impression-Severity (CGI-S) score ≥3; 5)Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for liver qi stagnation and spleen deficiency.
Exclusion Criteria:
1)Meet the diagnostic criteria for any psychiatric disorder other than obsessive-compulsive disorder (OCD), with the exception of obsessive-compulsive personality disorder (OCPD); 2)Meet the criteria for treatment-resistant obsessive-compulsive disorder (TR-OCD) as defined in the Chinese Guidelines for the Prevention and Treatment of Obsessive-Compulsive Disorder; 3) Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for any syndrome other than liver qi stagnation and spleen deficiency; 4)Women who are pregnant, planning to become pregnant in the near future, or breastfeeding; 5)Have a history of substance abuse within the past 12 months; 6) Have a history of severe drug allergies; 7)Have any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chai-Xia Ding-Zhi Powder Group
Drug: Chaixia Dingzhi Powder
Placebo Group
Drug: Placebo Group
Participants will receive Chai-Xia Ding-Zhi Powder as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage.
Participants will receive Chai-Xia Ding-Zhi Powder placebo as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage.
Y-BOCS Score
Time frame: 8 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
Shanghai Mental Health Center →